IDEXX Laboratories, Inc. $IDXX Stake Raised by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 183,818 shares of the company’s stock after acquiring an additional 6,649 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.23% of IDEXX Laboratories worth $117,439,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Empowered Funds LLC grew its position in IDEXX Laboratories by 6.6% during the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after purchasing an additional 95 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at $265,000. AlphaQuest LLC boosted its stake in shares of IDEXX Laboratories by 7.3% during the 2nd quarter. AlphaQuest LLC now owns 398 shares of the company’s stock valued at $213,000 after buying an additional 27 shares during the period. Focus Partners Advisor Solutions LLC grew its holdings in shares of IDEXX Laboratories by 34.8% during the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 1,053 shares of the company’s stock valued at $564,000 after acquiring an additional 272 shares in the last quarter. Finally, Brighton Jones LLC acquired a new position in shares of IDEXX Laboratories in the second quarter worth $351,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP George Fennell sold 11,345 shares of the company’s stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the sale, the executive vice president directly owned 9,823 shares of the company’s stock, valued at approximately $6,352,730.56. This represents a 53.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael G. Erickson sold 5,371 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the completion of the transaction, the executive vice president owned 12,693 shares of the company’s stock, valued at $7,963,334.34. This trade represents a 29.73% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 18,180 shares of company stock worth $11,626,996. 0.98% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on IDXX. BTIG Research cut their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Barclays dropped their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Stifel Nicolaus set a $775.00 price target on IDEXX Laboratories in a report on Monday, November 3rd. Wall Street Zen raised IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 7th. Finally, Piper Sandler dropped their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Seven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $783.33.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $660.71 on Friday. The firm has a fifty day moving average price of $673.82 and a two-hundred day moving average price of $668.93. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $769.98. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. The company has a market cap of $52.61 billion, a PE ratio of 50.55, a price-to-earnings-growth ratio of 3.99 and a beta of 1.67.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period in the prior year, the company posted $2.53 EPS. The firm’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.